CDK4 and breast cancer: Palbociclib was the first of the CDK4/6i to receive FDA approval, in February 2015, to treat postmenopausal women with metastatic BC [24], based on the results of two phase II clinical trials, PALOMA-1 (NCT00721409) and PALOMA-2 (NCT01740427).